← Back to Search

Sugammadex for Neuromuscular Blockade

Phase 4
Waitlist Available
Led By Ellen Hauck, DO PhD
Research Sponsored by Temple University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
has diagnosis of COPD or ILD
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-30 minutes
Awards & highlights

Study Summary

This trial will compare two drugs used to reverse the effects of neuromuscular blockade agents after an outpatient bronchoscopy.

Eligible Conditions
  • Neuromuscular Blockade
  • Chronic Obstructive Pulmonary Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have been diagnosed with chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-30 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Minutes to Return of Baseline Muscle Tone
Secondary outcome measures
Number of Minutes to Extubation

Trial Design

2Treatment groups
Active Control
Group I: SugammadexActive Control1 Intervention
Patients in this arm of the study will receive Sugammadex as the drug used to reverse neuromuscular blockade.
Group II: Neostigmine/GlycopyrrolateActive Control1 Intervention
Patients in this arm of the study will receive Neostigmine/Glycopyrrolate as the drugs used to reverse neuromuscular blockade

Find a Location

Who is running the clinical trial?

Temple UniversityLead Sponsor
294 Previous Clinical Trials
81,740 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,862 Previous Clinical Trials
5,049,642 Total Patients Enrolled
35 Trials studying Neuromuscular Blockade
42,827 Patients Enrolled for Neuromuscular Blockade
Ellen Hauck, DO PhDPrincipal InvestigatorLewis Katz School of Medicine at Temple University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are geriatric individuals eligible for this research endeavor?

"This study seeks to include individuals over the age of consent and below 89 years old."

Answered by AI

To what medical condition is the Neostigmine/Glycopyrrolate drug cocktail often prescribed?

"Neostigmine/Glycopyrrolate is mainly used to treat gastrointestinal issues, yet it has also been utilized in general surgery and to prevent post-operative urinary retention as well as chronic bronchitis."

Answered by AI

Have investigators conducted any prior research on Neostigmine/Glycopyrrolate?

"At this moment in time, there are 24 research initiatives associated with Neostigmine/Glycopyrrolate. 4 of these clinical trials have reached their third phase and the majority are located in Rochester, Minnesota; though participation opportunities span 1089 sites across the country."

Answered by AI

Is enrollment open for this experiment?

"As indicated by the clinicaltrials.gov database, this investigation is currently on the hunt for participants; it was first posted to the website in April 2021 and has since been updated twice as of late April 2022."

Answered by AI

Do I meet the criteria to be involved in this experiment?

"To meet the criteria of this clinical trial, applicants must have been diagnosed with neuromuscular blockade and be between 18 and 89 years old. The research team seeks to enrol 80 participants in total."

Answered by AI

What is the recruitment size for this trial?

"Affirmative. According to the information hosted on clinicaltrials.gov, this experiment is still looking for participants and was initially posted in April 2021 with its last update made a year later. 80 persons must be enrolled from 1 medical centre."

Answered by AI

Has the Federal Drug Administration endorsed Neostigmine/Glycopyrrolate for commercial use?

"Neostigmine/Glycopyrrolate has been approved for use, making it a relatively safe course of action. Subsequently, our team at Power assigned this treatment the highest safety rating of 3."

Answered by AI
~15 spots leftby Mar 2025